The efficacy of HDAC8 inhibition, crizotinib and the combination was assessed by evaluating tumor volume change, quantified via semi-automated image analysis, from day one (start of treatment) to day three (end of experiment) post-implantation. Here, HDAC8 is linked to neoplasm.